SCHEMBL717432

SCHEMBL717432

COC(=O)c1sc2cc(C(F)(F)F)ccc2c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
CFTR P13569 1/20 0.47
CISD2 Q8N5K1 1/20 0.44
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MCL1 Q07820 1/20 0.43
CES2 O00748 1/20 0.41
CSNK1D P48730 2/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 2/20 0.41
DYRK1A Q13627 1/20 0.41
KDM4E B2RXH2 2/20 0.40
GLA P06280 2/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719061 0.89 CISD2 (0.47) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL6844839 0.86 ALDH1A1 (0.48) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL693338 0.86 MAPT (0.51) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL2961556 0.85 ALDH1A1 (0.59) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL693546 0.85 ALDH1A1 (0.47) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL31079664 0.85 ALDH1A1 (0.59) ALDH1A1CFTRCISD2MAPTNPSR1
SCHEMBL2721181 0.84 GPR35 (0.54) ALDH1A1NPSR1MCL1LMNADYRK1A
SCHEMBL6840332 0.84 DYRK1A (0.44) ALDH1A1MAPTMCL1CES2CSNK1D
SCHEMBL6840329 0.83 MEN1 (0.40) ALDH1A1MAPTMCL1CES2CSNK1D
SCHEMBL1033653 0.83 ALDH1A1 (0.46) ALDH1A1CFTRCISD2MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
US-20100324013-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed
EP-1740568-B1 BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. SMITHKLINE BEECHAM CORP (US) 2008-11-26 EP disclosed
US-20070155805-A1 Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease SMITHKLINE BEECHAM CORPORATION 2007-07-05 US disclosed
US-20070155805-A1 Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease SMITHKLINE BEECHAM CORPORATION 2007-07-05 US disclosed
US-20070155805-A1 Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease SMITHKLINE BEECHAM CORPORATION 2007-07-05 US disclosed
EP-1740568-A2 BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. SMITHKLINE BEECHAM CORPORATION (US) 2007-01-10 EP disclosed
WO-2005077926-A2 BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885CFTR 190/4885CISD2 3294/4885
US-20100324013-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA ALDH1A1 364/4885CFTR 619/4885CISD2 1568/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885CFTR 190/4885CISD2 3294/4885
US-20070155805-A1 Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease ABAT, BPTF, TNNT2 ALDH1A1 224/4885CFTR 2842/4885CISD2 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.